AstraZeneca PLC (AZN)vsCencora Inc. (COR)
AZN
AstraZeneca PLC
$160.17
+0.33%
HEALTHCARE · Cap: $252.33B
COR
Cencora Inc.
$321.57
+0.19%
HEALTHCARE · Cap: $61.36B
Smart Verdict
WallStSmart Research — data-driven comparison
Cencora Inc. generates 442% more annual revenue ($332.77B vs $61.37B). AZN leads profitability with a 17.0% profit margin vs 0.8%. COR appears more attractively valued with a PEG of 0.68. COR earns a higher WallStSmart Score of 62/100 (C+).
AZN
Buy60
out of 100
Grade: C+
COR
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Margin of Safety
-70.5%
Fair Value
$188.60
Current Price
$321.57
$132.97 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Every $100 of equity generates 86 in profit
Safe zone — low bankruptcy risk
Large-cap with strong market position
Growing faster than its price suggests
Generating 2.4B in free cash flow
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
0.8% margin — thin
Operating margin of 1.4%
Trading at 20.1x book value
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : COR
The strongest argument for COR centers on Return on Equity, Altman Z-Score, Market Cap. PEG of 0.68 suggests the stock is reasonably priced for its growth.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : COR
The primary concerns for COR are Profit Margin, Operating Margin, Price/Book. Debt-to-equity of 3.84 is elevated, increasing financial risk. Thin 0.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
AZN profiles as a mature stock while COR is a value play — different risk/reward profiles.
COR carries more volatility with a beta of 0.57 — expect wider price swings.
AZN is growing revenue faster at 6.4% — sustainability is the question.
COR generates stronger free cash flow (2.4B), providing more financial flexibility.
Bottom Line
COR scores higher overall (62/100 vs 60/100). AZN offers better value entry with a 18.4% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Cencora Inc.
HEALTHCARE · MEDICAL DISTRIBUTION · USA
CoreSite Realty Corporation (NYSE: COR) delivers secure, reliable, high-performance data center, cloud access and interconnect solutions to a growing client ecosystem in eight key North American markets.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?